| pegylated liposomal doxorubicin / Generic mfg. |
NCT01016054: A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer |
|
|
| Terminated | 1b | 4 | US | AGS-8M4, Pegylated liposomal doxorubicin (PLD), gemcitabine, carboplatin | Astellas Pharma Inc, Agensys, Inc. | Carcinoma, Ovarian Cancer, Ovarian Diseases, Ovarian Neoplasms | 04/10 | 04/10 | | |
NCT00770536: AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR |
|
|
| Completed | 1b | 103 | US, Europe, RoW | A1: AMG 386 10 mg/kg + Liposomal doxorubicin, Liposomal doxorubicin, AMG 386, A3: AMG 386 15mg/kg + Liposomal doxorubicin, B1: AMG 386 10 mg/kg + Topotecan, Topotecan, B3: AMG 386 15mg/kg + Topotecan | Amgen | Cancer, Carcinoma, Fallopian Tube Cancer, Gynecological Malignancies, Metastases, Oncology, Ovarian Cancer, Solid Tumors, Tumors | 01/12 | 06/15 | | |
|
NCT00659178: Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer |
|
|
| Completed | 1 | 15 | US | SB-485232 (interleukin 18), pegylated liposomal doxorubicin, SB-485232 (interleukin 18), pegylated liposomal doxorubicin | GlaxoSmithKline | Neoplasms, Ovarian | 02/11 | 02/11 | | |
NCT01202890: Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer |
|
|
| Terminated | 1 | 1 | US | Lenalidomide, Liposomal Doxorubicin, Bevacizumab, Revlimid, Doxil, Avastin | New Mexico Cancer Care Alliance, Celgene Corporation | Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma | 05/11 | 05/12 | | |
NCT01227941: MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced Solid Tumors and Ovarian Cancer (MK-4827-011) |
|
|
| Terminated | 1 | 6 | US | MK-4827 + pegylated liposomal doxorubicin, Doxil, Caelyx | Tesaro, Inc. | Ovarian Cancer | 09/11 | 09/11 | | |
MORAb-003-005, NCT01004380: Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer |
|
|
| Completed | 1 | 15 | US | Farletuzumab, Carboplatin, and PLD, Farletuzumab (MORAb-003), Carboplatin, PLD | Morphotek | Epithelial Ovarian Cancer | 08/12 | 10/12 | | |
NCT01329549: Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC) |
|
|
| Terminated | 1 | 2 | Japan | BIBF 1120 (high) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min, BIBF 1120 (medium) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min, BIBF 1120 (low) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min | Boehringer Ingelheim | Ovarian Neoplasms | 10/12 | 10/12 | | |
NCT01279291: Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer |
|
|
| Terminated | 1 | 22 | US | KHK2866, Gemcitabine and Carboplatin, Gemzar, Paraplatin, paclitaxel, Taxol, pegylated liposomal doxorubicin, Doxil | Kyowa Kirin Co., Ltd., Kyowa Hakko Kirin Pharma, Inc. | Neoplasms, Ovarian Neoplasms, Fallopian Tube Neoplasms, Primary Peritoneal Neoplasm | 11/12 | 11/12 | | |
NCT01314105: BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer |
|
|
| Completed | 1 | 19 | Europe | BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min, BIBF 1120+ PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min | Boehringer Ingelheim | Ovarian Neoplasms, Peritoneal Neoplasms | 07/13 | 04/16 | | |
NCT01815294: A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer |
|
|
| Completed | 1 | 54 | US, Europe | DOXIL/CAELYX (doxorubicin) Treatment Sequence AB, DOXIL/CAELYX (doxorubicin) Treatment Sequence BA | Janssen Research & Development, LLC | Neoplasms, Neoplasms, Ovarian, Neoplasms, Breast, Advanced or Refractory Solid Malignancies | 12/14 | 12/14 | | |
NCT02081495: A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer |
|
|
| Completed | 1 | 35 | US, Canada, Europe | DOXIL/CAELYX reference product (Treatment A), DOXIL, CAELYX, DOXIL/CAELYX test product (Treatment B) | Janssen Research & Development, LLC | Neoplasms | 11/15 | 11/15 | | |
